Publication Cover
Synthetic Communications
An International Journal for Rapid Communication of Synthetic Organic Chemistry
Volume 52, 2022 - Issue 11-12
249
Views
7
CrossRef citations to date
0
Altmetric
Articles

Synthesis, antibacterial activity and in silico study of new bis(1,3,4-oxadiazoles)

, ORCID Icon & ORCID Icon
Pages 1421-1440 | Received 04 Apr 2022, Published online: 05 Jul 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Ahmed E. M. Mekky & Sherif M. H. Sanad. (2022) Microwave-assisted synthesis of nicotinonitrile and/or arene-linked bis(chromene-thiazoles) as new VRE and MRSA inhibitors. Synthetic Communications 52:24, pages 2276-2290.
Read now
Ahmed E. M. Mekky & Sherif M. H. Sanad. (2022) New thiazole-based bis(Schiff bases) linked to arene units as potential MRSA inhibitors. Synthetic Communications 52:23, pages 2205-2218.
Read now

Articles from other publishers (4)

Sherif M.H. Sanad & Ahmed E.M. Mekky. (2023) New bis(thieno[2,3- b ]pyridine) hybrids linked to arene units as potential bacterial biofilm and MRSA inhibitors . Canadian Journal of Chemistry 101:8, pages 538-547.
Crossref
Ahmed E. M. Mekky & Sherif M. H. Sanad. (2023) Synthesis of New Pyrazolo[1,5‐ a ]pyrimidines as Potential Antibacterial Agents: In Vitro and In Silico Study . ChemistrySelect 8:17.
Crossref
Ndama Faye, Bédié Mbow, Aïssatou Alioune Gaye, Cheikh Ndoye, Mayoro Diop, Grégory Excoffier & Mohamed Gaye. (2022) Syntheses and Antioxidant Activity of 1-Isonicotinoyl-4-phenylthiosemicarbazide and Crystal Structures of N-Phenyl-5-(pyridin-4-yl)-1,3,4-oxadiazol-2-amine Hydrochloride and 4-Phenyl-3-(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione derived from 1 Isonicotinoyl-4-phenylthiosemicarbazide. Earthline Journal of Chemical Sciences, pages 189-208.
Crossref
Sherif M. H. Sanad, Ahmed E. M. Mekky & Ahmed A. M. Ahmed. (2022) Tandem synthesis, cytotoxicity, and in silico study of new 1,3,4‐oxadiazoles as potential thymidylate synthase inhibitors. Archiv der Pharmazie 355:10.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.